{"prompt": "['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'Cmax: maximum observed serum concentration', 'Ctrough: serum concentration observed pre-dose at Visits 2, 3 and 4', 'Rac: accumulation ratio, calculated as Visit 4 Cmax /Visit 1 Cmax', '8.5.', 'Interim Analyses', 'Not applicable', '9.', 'QUALITY CONTROL AND QUALITY ASSURANCE', '9.1.', \"Investigator's Responsibility\", 'The Investigator will comply with the protocol (which has been approved/given favorable', 'opinion) by the Ethics Committee, ICH GCP, and applicable regulatory requirements. The', 'Investigator is ultimately responsible for the conduct of all aspects of the trial at the trial site', 'and verifies by signature the integrity of all data transmitted to the Sponsor. The term', '\"Investigator\" as used in this protocol as well as in other trial documents, refers to the', 'Investigator or authorized trial personnel that the Investigator has designated to perform', 'certain duties. Sub-Investigators or other authorized trial personnel are eligible to sign for the', \"Investigator, except where the Investigator's signature is specifically required.\", 'argenx BVBA', 'Confidential', 'Page 91 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', '9.2.', 'Quality Control of Data', 'Quality control will be applied to each stage of data handling.', 'The following steps will be taken to ensure the accuracy, consistency, completeness, and', 'reliability of the data:', 'Investigator meetings.', 'Central laboratories for clinical laboratory parameters and ECGs.', 'Site initiation visit.', 'Routine site monitoring.', 'Ongoing site communication and training.', 'Ongoing oversight by Clinical Trial Monitors of safety parameters and adherence to', 'selection criteria.', 'Data management quality control checks.', 'Continuous data acquisition and cleaning.', 'Quality control check of the CTR.', 'To avoid inter-observer variability, every effort should be made to ensure that the same', 'individual who made the initial Baseline determinations completes all efficacy and', 'safety evaluations.', \"In addition, Sponsor and/or Sponsor's designated CRO Clinical Quality Assurance (CQA)\", 'Department may conduct periodic audits of the trial processes, including, but not limited to', 'trial site, or site visits, central laboratories, vendors, clinical database, and final CTR. When', 'audits are conducted, access must be authorized for all trial-related documents including', \"medical history and concomitant medication documentation to authorized Sponsor's\", 'representatives and regulatory authorities.', '9.3.', 'Monitoring', 'The Sponsor has engaged the services of a CRO to perform all clinical trial monitoring', \"functions within this clinical trial. Sponsor's designated CRO monitors will work in\", 'accordance with SOPs of the CRO.', 'Monitoring visits must be conducted according to the applicable ICH-GCP guidelines to', 'verify that, amongst others, the:', 'Data are authentic, accurate, and complete.', 'Safety and rights of subjects are being protected.', 'argenx BVBA', 'Confidential', 'Page 92 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'Trial is conducted in accordance with the currently approved protocol, any other trial', 'agreements and all applicable regulatory requirements.', 'The Investigator and the head of the medical institution (where applicable) agrees to allow', 'the Clinical Trial Monitor direct access to all relevant documents.', 'The Investigator must ensure provision of reasonable time, space and qualified personnel for', 'monitoring visits.', 'The Clinical Trial Monitor will perform an eCRF review and Source Document Verification', '(SDV).', 'The Source Documentation Agreement Form describes the source data for the different data', 'in the eCRF. This document should be completed and signed by the Clinical Trial Monitor', \"and Investigator and should be filed in the Investigator's trial file. Any data item for which\", 'the eCRF will serve as the source must be identified, agreed and documented in the Source', 'Documentation Agreement Form.', 'Upon completion or premature discontinuation from the trial, the Clinical Trial Monitor will', 'conduct site closure activities with the Investigator and site staff as appropriate, in', 'accordance with applicable regulations, ICH GCP guidelines and CRO/Sponsor procedures.', '9.4.', 'Data Management', 'Data generated within this clinical trial will be handled according to the SOPs of the Data', \"Management and Biostatistics departments of the Sponsor's designated CRO.\", 'Case report forms are provided for each patient in electronic format. It will be transcribed by', 'the trial site staff from the source documents onto the eCRF. Date must be entered in English', \"and guidelines for eCRF completion, including the collection of Investigator's e-signature,\", 'will be provided by the CRO. Appropriate training and security measures will be completed', 'with the Investigator and all authorized trial site staff prior to the trial being initiated and any', 'data being entered into the system for any trial patient at the site.', 'The eCRF is essentially considered a data entry form and should not constitute the original', '(or source) medical records unless otherwise specified. Source documents are all documents', \"used by the Investigator or hospital that relate to the patient's medical history, that verify the\", 'existence of the patient, the inclusion and exclusion criteria, and all records covering the', \"patient's participation in the trial. They can include laboratory notes, ECG results,\", 'memoranda, pharmacy dispensing records, patient files, etc. The eCRFs should be completed', 'by the Investigator or a qualified designee from the site as soon as the data are available.', 'As a matter of regulation, the Investigator is responsible for the accuracy and authenticity of', 'all clinical data entered onto eCRFs. Prior to database lock, each completed eCRF must be', 'reviewed for accuracy by the Investigator, corrected as necessary and then approved. The', \"Investigator's e-signature serves to attest that the information contained on the eCRFs has\", 'argenx BVBA', 'Confidential', 'Page 93 of 110']\n\n###\n\n", "completion": "END"}